<DOC>
	<DOCNO>NCT03060148</DOCNO>
	<brief_summary>Previous study show spinal cord stimulation ( SCS ) may improve cardiac output decrease risk ischemic ventricular arrhythmia animal model safety profile human trial . The purpose study evaluate feasibility , treatment efficacy safety SCS patient severe symptomatic heart failure ( HF ) .</brief_summary>
	<brief_title>Spinal Cord Stimulation Heart Failure</brief_title>
	<detailed_description>Morbidity mortality heart failure ( HF ) patient remain high , even recent advance therapy . Previous study show autonomic nervous system play important role pathophysiology HF sudden cardiac death . Spinal cord stimulation ( SCS ) neurostimulation therapy , involve stimulation select nerve fiber intend create end-organ response characterize change blood flow , decrease catecholamine reduction inflammation . The SCS system consist implantable pulse generator ( IPG ) dual lead . Each lead electrodes distal end . Electrical impulse travel IPG lead electrode position select nerve fiber provide therapeutic stimulation . By virtue potential augmenting blood flow , decrease catecholamine reduce inflammation , SCS may benefit HF patient .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Patients leave ventricular ejection fraction 20 % 35 % Patient New York Heart Association Class III Ambulatory Class IV Patient receive stable medical therapy HF ( &gt; 90 day ) baseline Patient leave ventricular end diastolic diameter 55 mm 80 mm Patient must able willing provide write informed consent participate study Patient must able willing comply require followup schedule Patient currently implant spinal cord stimulator previously implant upper thoracic spinal cord stimulator explanted Patient polyneuropathy Patient require shortwave diathermy , microwave diathermy therapeutic ultrasound diathermy Patient receive tissue/organ transplant ( expect tissue/organ transplant within next 180 day ) Patient persistent permanent atrial fibrillation Patient chronic refractory angina peripheral vascular pain Patient critical valvular heart disease require valve repair replacement Patient myocardial infarction ( MI ) cardiac revascularization procedure ( percutaneous coronary intervention coronary artery bypass graft ) &lt; 90 day baseline expect next 180 day Patient IV inotropic therapy Patient active myocarditis early postpartum cardiomyopathy Patient take follow drug within 30 day enrollment : systemic corticosteroid , cytostatic immunosuppressive drug therapy ( cyclophosphamide , methotrexate , cyclosporine , azathioprine , etc . ) , DNA deplete cytotoxic drug Patient pregnant , childbearing potential use adequate contraceptive method , nurse Patient bleeding tendency ( International Normalized Ratio &gt; 1.2 platelet count &lt; 100 x10^9 per liter ) Patient local infection implantable cardioverterdefibrillator ( ICD ) implant location systemic infection Patient renal insufficiency ( creatinine &gt; 3.0 mg/dl ) Patient participate another clinical study Patient le 20 year old Patient ` life ` expectancy le 1 year assess investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Heart failure</keyword>
	<keyword>Spinal cord stimulation</keyword>
</DOC>